FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989707515> ?p ?o ?g. }

• W2989707515 endingPage "422" @default.
• W2989707515 startingPage "422" @default.
• W2989707515 abstract "Background With lymphoma survival rates increasing and a growing population of long-term survivors, the development of cardiovascular disease (CVD) in this patient population is of increasing importance. Anthracyclines are critical in the management of many lymphoma subtypes. However, there is a risk of developing anthracycline-induced CVD. Here, we estimate the cumulative incidence of CVD in adult lymphoma survivors and investigate risk factors associated with post diagnosis CVD. Methods Participants were from the Mayo component of the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE). From 2002-2015, the MER offered enrollment to all patients with newly diagnosed lymphoma who are US residents and age &gt;18 years. Participants completed a risk factor questionnaire, and clinical and treatment data were abstracted from medical records. Patients were contacted every 6 months for the first 3 years after diagnosis and annually thereafter to assess disease status, re-treatment and new onset morbidity including CVD. CVD events, including congestive heart failure (CHF), coronary artery disease (CAD), valvular heart disease (VHD), and arrhythmia were identified and validated against medical records. CHF was validated with the Cardiovascular Health Study Criteria and/or the Framingham Criteria. CAD, arrhythmia, and VHD were validated using clinical definitions. We calculated the cumulative incidence of CVD, with death modeled as a competing risk. The association of risk factors and treatments with risk of CVD was estimated using hazard ratios (HR) and 95% confidence intervals (CI) from Cox regression with a competing risk of death. Risk factors included age, sex, diabetes, smoking, body mass index (BMI), and treatment with anthracyclines or radiation therapy. Results The study consisted of 3,063 lymphoma patients after excluding those with chronic lymphocytic leukemia and CVD prior to lymphoma diagnosis. The median age at diagnosis was 59 years (range 18-95), and 56% were males. At a median follow-up was 6.9 years (range 0.8-17.1), 640 patients (21%) had died without CVD and 485 patients self-reported CVD post lymphoma diagnosis, of which 280 (57.7%) were validated. Cardiovascular events included 86 CHF, 78 CAD, 40 VHD, and 164 arrhythmias. The cumulative incidence of CVD (Figure 1) at 5 and 10 years was 6.0% (95% 5.2%-7.0%) and 10.7% (95% CI 9.5%-12.1%), respectively. In multivariable analysis, increasing age (HR=3.93 per 5 years, p&lt;0.001), male sex (HR=1.33, p=0.03), former smoker (HR=1.04, p=0.77), current smoker (HR=1.96, p&lt;0.001), BMI&gt;30 kg/m2 (HR=1.50, p=0.01), and anthracycline treatment (HR=1.49. p&lt;0.001) were all significantly associated with risk of overall CVD, while there was no association with diabetes (HR=0.92, p=0.70) or radiation therapy (HR=1.05, p=0.78) in the multivariable model. Anthracycline use was significantly associated with increased risk of CHF (HR=2.64, p&lt;0.001) and arrhythmia (HR=1.51, p&lt;0.01), but not VHD (HR=0.83, p=0.56) or CAD (HR=1.23, p=0.31) after adjustment for the cardiac risk factors. The number of anthracycline cycles ranged from 0 to 12. 63.2% of individuals that received anthracyclines received 6 cycles. The 5-year cumulative incidence of CVD for 0, 1-5, 6, and &gt;6 anthracycline cycles was 5%, 6.9%, 7.4%, and 7.7%, respectively. Adjusting for cardiac risk factors, the number of anthracycline cycles was significantly associated with increased risk of CVD (1-5 cycles HR=1.34, p=0.11; 6 cycles HR=1.51, p&lt;0.01; &gt;6 cycles HR=2.04, p=0.03). Furthermore, the number of anthracycline cycles was associated with CHF (1-5 cycles HR=2.82, p&lt;0.001; 6 cycles HR=2.46, p&lt;0.001; &gt;6 cycles HR=5.33, p&lt;0.001) and arrhythmia (1-5 cycles HR=1.31, p=0.27; 6 cycles HR=1.60, p&lt;0.01; &gt;6 cycles HR=1.65, p=0.27). Conclusions In the modern treatment era, the risk of new onset CVD in patients with lymphoma without a history of CVD is approximately 1% per year after diagnosis. Arrhythmia and CHF were the most commonly occurring CVD events in this cohort. Both traditional CVD risk factors and treatment with anthracyclines was associated with an increased risk of developing CVD, and anthracyclines were a risk factor for arrhythmia and CHF in particular. Prevention of CVD in lymphoma patients will need to address both treatment and traditional lifestyle factors. Figure 1 Disclosures Maurer: Morphosys: Membership on an entity's Board of Directors or advisory committees; Nanostring: Research Funding; Celgene: Research Funding. Nowakowski:Selvita: Membership on an entity's Board of Directors or advisory committees; Genentech, Inc.: Research Funding; F. Hoffmann-La Roche Ltd: Research Funding; Curis: Research Funding; Bayer: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; NanoString: Research Funding; MorphoSys: Consultancy, Research Funding. Cerhan:NanoString: Research Funding; Celgene: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees." @default.
• W2989707515 created "2019-12-05" @default.
• W2989707515 creator A5001155718 @default.
• W2989707515 creator A5008724119 @default.
• W2989707515 creator A5011479243 @default.
• W2989707515 creator A5020978640 @default.
• W2989707515 creator A5024819739 @default.
• W2989707515 creator A5025688165 @default.
• W2989707515 creator A5047509474 @default.
• W2989707515 creator A5061713890 @default.
• W2989707515 creator A5062214120 @default.
• W2989707515 creator A5067100969 @default.
• W2989707515 creator A5071201232 @default.
• W2989707515 creator A5076621021 @default.
• W2989707515 creator A5077867282 @default.
• W2989707515 creator A5079709028 @default.
• W2989707515 creator A5080184636 @default.
• W2989707515 date "2019-11-13" @default.
• W2989707515 modified "2023-10-16" @default.
• W2989707515 title "Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era" @default.
• W2989707515 doi "https://doi.org/10.1182/blood-2019-127203" @default.
• W2989707515 hasPublicationYear "2019" @default.
• W2989707515 type Work @default.
• W2989707515 sameAs 2989707515 @default.
• W2989707515 citedByCount "0" @default.
• W2989707515 crossrefType "journal-article" @default.
• W2989707515 hasAuthorship W2989707515A5001155718 @default.
• W2989707515 hasAuthorship W2989707515A5008724119 @default.
• W2989707515 hasAuthorship W2989707515A5011479243 @default.
• W2989707515 hasAuthorship W2989707515A5020978640 @default.
• W2989707515 hasAuthorship W2989707515A5024819739 @default.
• W2989707515 hasAuthorship W2989707515A5025688165 @default.
• W2989707515 hasAuthorship W2989707515A5047509474 @default.
• W2989707515 hasAuthorship W2989707515A5061713890 @default.
• W2989707515 hasAuthorship W2989707515A5062214120 @default.
• W2989707515 hasAuthorship W2989707515A5067100969 @default.
• W2989707515 hasAuthorship W2989707515A5071201232 @default.
• W2989707515 hasAuthorship W2989707515A5076621021 @default.
• W2989707515 hasAuthorship W2989707515A5077867282 @default.
• W2989707515 hasAuthorship W2989707515A5079709028 @default.
• W2989707515 hasAuthorship W2989707515A5080184636 @default.
• W2989707515 hasBestOaLocation W29897075151 @default.
• W2989707515 hasConcept C107130276 @default.
• W2989707515 hasConcept C11783203 @default.
• W2989707515 hasConcept C120665830 @default.
• W2989707515 hasConcept C121332964 @default.
• W2989707515 hasConcept C126322002 @default.
• W2989707515 hasConcept C207103383 @default.
• W2989707515 hasConcept C2778198053 @default.
• W2989707515 hasConcept C2778213512 @default.
• W2989707515 hasConcept C2779134260 @default.
• W2989707515 hasConcept C2908647359 @default.
• W2989707515 hasConcept C44249647 @default.
• W2989707515 hasConcept C50382708 @default.
• W2989707515 hasConcept C50440223 @default.
• W2989707515 hasConcept C61511704 @default.
• W2989707515 hasConcept C71924100 @default.
• W2989707515 hasConcept C72563966 @default.
• W2989707515 hasConcept C88879693 @default.
• W2989707515 hasConcept C99454951 @default.
• W2989707515 hasConceptScore W2989707515C107130276 @default.
• W2989707515 hasConceptScore W2989707515C11783203 @default.
• W2989707515 hasConceptScore W2989707515C120665830 @default.
• W2989707515 hasConceptScore W2989707515C121332964 @default.
• W2989707515 hasConceptScore W2989707515C126322002 @default.
• W2989707515 hasConceptScore W2989707515C207103383 @default.
• W2989707515 hasConceptScore W2989707515C2778198053 @default.
• W2989707515 hasConceptScore W2989707515C2778213512 @default.
• W2989707515 hasConceptScore W2989707515C2779134260 @default.
• W2989707515 hasConceptScore W2989707515C2908647359 @default.
• W2989707515 hasConceptScore W2989707515C44249647 @default.
• W2989707515 hasConceptScore W2989707515C50382708 @default.
• W2989707515 hasConceptScore W2989707515C50440223 @default.
• W2989707515 hasConceptScore W2989707515C61511704 @default.
• W2989707515 hasConceptScore W2989707515C71924100 @default.
• W2989707515 hasConceptScore W2989707515C72563966 @default.
• W2989707515 hasConceptScore W2989707515C88879693 @default.
• W2989707515 hasConceptScore W2989707515C99454951 @default.
• W2989707515 hasIssue "Supplement_1" @default.
• W2989707515 hasLocation W29897075151 @default.
• W2989707515 hasOpenAccess W2989707515 @default.
• W2989707515 hasPrimaryLocation W29897075151 @default.
• W2989707515 hasRelatedWork W1971184210 @default.
• W2989707515 hasRelatedWork W2056357418 @default.
• W2989707515 hasRelatedWork W2104431466 @default.
• W2989707515 hasRelatedWork W2403614928 @default.
• W2989707515 hasRelatedWork W2572837865 @default.
• W2989707515 hasRelatedWork W2606338401 @default.
• W2989707515 hasRelatedWork W3025637185 @default.
• W2989707515 hasRelatedWork W3201888939 @default.
• W2989707515 hasRelatedWork W33073900 @default.
• W2989707515 hasRelatedWork W4206419806 @default.
• W2989707515 hasVolume "134" @default.
• W2989707515 isParatext "false" @default.
• W2989707515 isRetracted "false" @default.
• W2989707515 magId "2989707515" @default.
• W2989707515 workType "article" @default.